Navigation Links
Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/14/2012

SAN MATEO, Calif., March 14, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session, March 24-26th. Location: McCormick Place South, Hall A Date: Monday, March 26, 2012 Time: 10:00 AM -12:00 PM (CT) Poster Presentation: Board #628  Presenter: Hsiao D. Lieu, MD, FACC Title: "Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure"About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the annual inpatient cost of heart failure.

About Nile TherapeuticsNile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. The cenderitide program was granted Fast Track status by the United States Food and Drug Administration. More information on Nile can be found at http://www.nilethera.com.


'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
2. ADHD Therapeutics Reviewed by NeuroPerspective
3. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
4. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
5. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
6. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
7. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
8. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
9. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
10. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
11. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):